Kura Oncology

KURA

Market cap $713M

Overview Fund Activity

8.21 USD

+0.02

0.24%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

8.27

+0.06

0.73%

1 day

0.24%

5 days

0.86%

1 month

11.85%

3 months

26.5%

6 months

12.62%

Year to date

-5.41%

1 year

-60.66%

5 years

-71.02%

10 years

4.72%

About: Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Employees: 192

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

93% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 44

66% more call options, than puts

Call options by funds: $434K | Put options by funds: $261K

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

3% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 29

1% less funds holding

Funds holding: 184 [Q1] → 182 (-2) [Q2]

4.75% less ownership

Funds ownership: 99.66% [Q1] → 94.9% (-4.75%) [Q2]

11% less capital invested

Capital invested by funds: $531M [Q1] → $474M (-$57.2M) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$24

192% upside

Avg. target

$30

265% upside

High target

$36

338% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Reni J. Benjamin	$24	Market Outperform Maintained	11 Aug 2025
Wedbush Robert Driscoll	$36	Outperform Reiterated	20 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about KURA published over the past 30 days

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Kura Oncology, Inc. (NASDAQ:KURA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Troy Wilson - Chairman, CEO & President Brian Powl - Chief Commercial Officer Conference Call Participants Frank Tang - Morgan Stanley Presentation Frank Tang Managing Director All right. Good afternoon, everyone.

Kura Oncology, Inc. (KURA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September.

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Brian T. Powl - Chief Commercial Officer Greg Mann - Corporate Participant Mollie Leoni - Chief Medical Officer Thomas Doyle - Senior Vice President of Finance & Accounting Troy Edward Wilson - Chairman, CEO & President Conference Call Participants Ellen Horste - TD Cowen, Research Division Eric Tatenda Musonza - UBS Investment Bank, Research Division Jason Eron Zemansky - BofA Securities, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Peter Green - Unidentified Company Peter Richard Lawson - Barclays Bank PLC, Research Division Roger Song - Jefferies LLC, Research Division Suranjit Mukherjee - BTIG, LLC, Research Division Wei Ji Chang - Leerink Partners LLC, Research Division Operator Hello, and welcome, everyone, joining today's Second Quarter 2025 Kura Oncology, Inc. Financial Results Conference Call.

Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

Kura Oncology (KURA) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of $0.15. This compares to a loss of $0.59 per share a year ago.

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

The Motley Fool

Kura (KURA) Revenue Drops 61%

Kura (KURA) Revenue Drops 61%

Kura (KURA) Revenue Drops 61%

Kura Oncology Reports Second Quarter 2025 Financial Results

– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with regulatory review timeline – – KOMET-017-IC (intensive chemotherapy) and NIC (non-intensive chemotherapy) phase 3 studies in newly diagnosed AML on track to start in 2H 2025 – – Three clinical abstracts from Kura's farnesyl transferase inhibitors (FTI) development program accepted for presentation at the 2025 ESMO Congress – – $630.7 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2025 financial results and provided a corporate update.

Kura Oncology Reports Second Quarter 2025 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on August 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 646,700 shares of common stock to thirty-five (35) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Second Quarter 2025 Financial Results

SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second quarter 2025 financial results after the close of U.S. financial markets on Thursday, August 7, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update.

Kura Oncology to Report Second Quarter 2025 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™